Efficacy of a Dietary Supplementation in Reducing Hospital Admissions for COVID-19. Randomized Clinical Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

252 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-09

Study Completion Date

2023-10-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A double-blind, placebo-controlled, randomized clinical trial to assess efficacy of micronutrient dietary supplementation in reducing hospital admissions for COVID-19 and incidence of Long Covid.

We want to assess the need for hospital admission for severe acute respiratory syndrome Corona Virus-2 (SARS-CoV-2) infection in outpatients diagnosed of COVID-19 disease, taking a micronutrient supplementation for 14 days. The outcome Will be measured within 1 month after beginning the study treatment. The patients will be followed-up for a period of 180 days for the incidence of Long Covid

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dietary Supplements for COVID-19

NCT04780061

Covid19

TERMINATED PHASE3

Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19

NCT04877509

Covid19

COMPLETED

Beta-glucans for Hospitalised Patients With COVID-19

NCT05465798

COVID-19

UNKNOWN PHASE2

Oral Nutritional Supplements in Treatment of Elderly Mild-to-Moderate COVID-19

NCT05629975

Nutrition, Healthy

UNKNOWN NA

A Trial of Oral Nutritional Supplements on Nutritional Status and Clinical Outcomes

NCT01190969

Malnutrition

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Type of study/ Design: Randomized, double-blind, placebo-controlled clinical trial.
* Sponsor: Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol / Hospital Universitari Germans Trias i Pujol ( IGTP / HUGTIP)
* Title of the clinical trial: Efficacy of micronutrient dietary supplementation in reducing hospital admissions for COVID-19 and Long Covid: A double-blind, placebo-controlled, randomized clinical trial.
* Protocol code: CoVIT Clinical Trial
* NºClinicaltrials.gov: Pending
* Coordinating researcher: Dra. Teresa-Maria Tomasa-Irriguible.
* Recruiting Center: Germans Trias i Pujol University Hospital (HUGTIP)
* Ethical Committee for clinical Investigation (CEI): Germans Trias i Pujol University Hospital CEI.
* Monitoring: Clinical Research Associate at UPIC (Unitat Polivalent d'Investigació Clínica) Clinical Trial Unit- IGTP
* Study treatments: Dietary supplement with micronutrients and Placebo
* Test phase: Not applicable.
* Main objective: Evaluation of the effectiveness of supplementation with a dietary supplement to improve the need for hospital admission for SARS-CoV-2 infection, and incidence of Long Covid.
* Study pathology: COVID-19.
* Main variable: The need for hospital admission of SARS-CoV-2 documented infection and the incidence of Long Covid
* Study population and total number of patients: Patients of the health system of the Northern Metropolitan Area of Catalan Health Institution with symptoms compatible with SARS-CoV-2 infection. A total of 300 people (150 treated with dietary supplement and 150 with placebo).
* Duration of treatment: 14 days.
* Patients follow-up: 180 days

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A double-blind, placebo-controlled, randomized clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Placebo tablets with the same external aspect than the dietary supplement, the same administration route, containing only the excipients

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Micronutrient dietary supplement effervescent tablet

Tablet containing:

* Retinol (Vitamin A) 700 mcg
* Cholecalciferol (Vitamin D3) 10 mcg
* Alpha-Tocopherol (Vitamin E) 45 mg
* Ascorbic acid (vitamin C) 1000 mg
* Pyridoxine (Vitamin B6) 6.5 mg
* Cyanocobalamin (Vitamin B12) 9.6 mg
* Folic acid 400 mg
* Iron 5 mg
* Zinc 10 mg
* Selenium 110 mg
* Copper 0.9 mg
* Excipients

Group Type EXPERIMENTAL

Vitamin and trace elements

Intervention Type DIETARY_SUPPLEMENT

Dietary supplement oral route, once a day, during 14 days

Placebo dietary supplement effervescent tablet

Effervescent tablet with only the excipients.

* Sucralose 13 mg
* Sodium Chloride 20 mg
* Potassium Acesulfam 22.5 mg
* Orange P 55 mg
* Sodium Carbonate 70 mg
* Betacarotene 100 mg
* Malic Acid 800 mg
* Citric Acid 960 mg
* Sodium bicarbonate 1,000 mg
* Isomalt 1,459.50 mg

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Dietary supplement (placebo) oral route, once a day, during 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin and trace elements

Dietary supplement oral route, once a day, during 14 days

Intervention Type DIETARY_SUPPLEMENT

Placebo

Dietary supplement (placebo) oral route, once a day, during 14 days

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed Consent Form signed.
2. Patients with symptoms compatible with COVID-19: cough and fever who not fulfil criteria of hospitalization and will be in outpatient care.
3. Positive polymerase chain reaction (PCR) or transcription-mediated amplification (TMA) test or rapid antigen test for severe acute respiratory syndrome Corona Virus-2 (SARS-CoV-2) or diagnostic test available.
4. Age ≥ 18 years
5. Availability to meet the requirements of the protocol.

Exclusion Criteria

1. Intake of any micronutrient supplement during the month prior to inclusion.
2. Patients fulfilling hospitalization criteria.
3. Previous allergies to the micronutrient components and excipients.
4. Age ≥ 90 years with any comorbidity (diabetes, hypertension, obesity, heart disease, respiratory disease)
5. Participation in other research that requires experimental intervention (does not include observational studies) in the previous month before signing the informed consent form.
6. Detection by the researcher of lack of knowledge or willingness to participate and comply with all the requirements of the protocol.
7. Any other findings that at the discretion of the researcher may compromise protocol performance or significantly influence the interpretation or results of the effects of the nutritional supplement
8. Pregnancy or breastfeeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No